Certara rises after Q1 preliminary results, share repurchase program 

** Shares of drug development software provider Certara CERT rise 7.8% to $13.91

** Co expects prelim Q1 revenue of $106 million, above analysts' average estimate of $104.4 million as per data compiled by LSEG

** CERT expects 2025 revenue in the range of $415 million to $425 million, analysts' on average expect 2025 revenue of $419.8 million

** Co says its board has authorized a $100 million share repurchase program

** Separately, co launches an AI-enabled clinical assistance software to aid drug development that will reduce, refine, or replace animal testing

** The move comes after the U.S. FDA said it plans to replace animal testing in the development of monoclonal antibody therapies and other drugs with "human-relevant methods," including the use of AI-based models

** Including session's move, CERT up 31.2% YTD